Who is sponsoring NCT06095258?

NCT06095258 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT06095258?

Interventions in NCT06095258: Traditional Chinese medicine treatment, Western medicine treatment.

What condition does NCT06095258 study?

NCT06095258 studies Long COVID.

Is NCT06095258 still recruiting?

NCT06095258 is currently status unknown. Last updated 26 October 2023.

Last reviewed 2023-10-26 · How we verify

NCT06095258

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics.

Status unknown Phase 2 Last updated 26 October 2023

What this trial tests

Phase 2 trial testing Traditional Chinese medicine treatment in Long COVID in 162 participants. Status unknown.

Timeline

1 December 2023

Primary endpoint
30 November 2025

28 February 2026

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	162
Start date	1 December 2023
Primary completion	30 November 2025
Estimated completion	28 February 2026

Drugs / interventions tested

Traditional Chinese medicine treatment — full drug profile →
Western medicine treatment — full drug profile →

Conditions studied

Long COVID — all drugs for Long COVID →

Sponsor

Chinese University of Hong Kong

Who can join

Adults 6 to 80, any sex, with Long COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, outcome assessor-blinded, practical randomized controlled trial, aiming to compare the actual clinical effectiveness of individualized traditional Chinese medicine and conventional Western medicine in the treatment of long COVID. Totally 162 patients with long COVID recruited into the study will be randomly assigned to the traditional Chinese medicine treatment group or the Western medicine control group. Patients in the treatment group will receive individualized TCM syndrome differentiation treatment, and patients in the control group will receive conventional Western medicine symptomatic treatment from general Western medicine practitioners for 4 weeks. All patients were followed up once a week (±2 days) during treatment period and followed up by 4 weeks (±2 days) after the treatment. Outcome measurements will be conducted at baseline, the end of treatment (week 4 ±2 days) and the follow-up visit (week 8 ±2 days).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Long COVID

Currently open trials in the same condition.

NCT05931497 — Sauna for Long Covid · NA · recruiting
NCT06452095 — Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy fo · NA · recruiting
NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting
NCT07435805 — Long-Term Health Effects of Previous COVID-19 in Patients Undergoing Preoperative Anesthesia Evaluation · recruiting
NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06095258 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 26 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06095258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing